Rundo International Pharmaceutical Research & Development Co., Ltd. (Rundo), a Shanghai-headquartered contract research organization (CRO) has selected eClinical solutions from OmniComm Systems, Inc. a global provider of clinical data management technology. Under the terms of two separate agreements, Rundo will use OmniComm’s TrialMaster EDC and TrialOne for research.
Rundo’s customers in China include domestic and multinational companies, with research ranging from Phase I through IV clinical trials. After comprehensive evaluations, Rundo selected OmniComm’s eClinical solutions for multiple reasons, including the availability of mature and validated systems, multiple therapeutic areas of experience, support of industry standards and competitive pricing. Additionally, OmniComm’s eClinical solutions provide market-leading technology for early phase research and Phase II-IV studies.
As a system that is compliant with global industry standards, TrialMaster allows user organizations to ensure the quality and integrity of data collected and managed during an entire set of studies. TrialMaster also enables users to comply with China’s FDA (NMPA) regulations and approval process for new drugs, and comply with regulations from the U.S. FDA and the EMA.
TrialOne reduces timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time Bedside Data Collection (BDC), direct data capture from devices, and automated processing of laboratory samples. These factors enhanced the confidence of Rundo to set up the industry-leading early phase clinics and deliver top service to the customers.
For more information, visit www.omnicomm.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.